Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV intranasal vaccine
- Development stage
- Preclinical
- Lead developer
- BlueWillow Biologics
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
The HIV intranasal vaccine is a preclinical vaccine candidate being developed by BlueWillow Biologics in collaboration with Medigen Vaccine Biologics for the prevention or treatment of HIV/AIDS. The vaccine utilizes BlueWillow's proprietary NanoVax (NE01) platform, which is a unique oil-in-water nanoemulsion adjuvant. This platform is specifically designed for intranasal administration to elicit both robust mucosal and systemic immune responses. By inducing mucosal immunity (including secretory IgA) at the site of viral entry, the vaccine aims to provide a first line of defense against HIV infection, while also generating systemic IgG and T-cell responses. The nanoemulsion adjuvant acts by enhancing the delivery of HIV antigens to dendritic cells and promoting a balanced Th1/Th2/Th17 immune response without the need for inflammatory toxins.
- Other names
- HIV/AIDS Intranasal VaccineNanoVax HIV vaccine
Beyond the preview
Go deeper on HIV intranasal vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV intranasal vaccine.